期刊文献+

缺血预处理联合停搏液对未成熟兔心脏的保护作用 被引量:2

Ischemic preconditioning plus cardioplegia in immature rabbit hearts
暂未订购
导出
摘要 目的 利用Langendorff模型研究缺血预处理 (IschemicPreconditioning,IPC)联合高钾停搏液对兔未成熟心脏缺血再灌注损伤的影响。方法 幼兔 (14~ 2 1d)离体灌注心脏 ,经历 5min缺血、10min再灌的IPC处理后 ,使用St.ThomasⅡ号液使其停跳 ,观察其在生理体温 (39℃ )下接受 4 5min缺血、4 0min再灌注后血流动力学、冠脉流出液心肌酶及心肌能量变化。结果 IPC联合高钾停搏液组较单纯高钾停搏液组再灌注后心率 (HR)、冠脉流出量 (CF)、左室发展压 (LVDP)及左室最大上升和下降速率 (±dp/dt)的恢复率明显改善 ,并保存了心肌ATP含量 ,减少了肌酸磷酸激酶同工酶 (CK MB)漏出。 Objective We investigated whether immature hearts experiencing global ischemia and reperfusion injury could be protected by ischemic preconditioning (IPC) under the use of cardioplegia. Methods Aerobically perfused in Langendorff mode at 39℃, isolated immature rabbit hearts (14~21 days old) were subjected to a IPC stimulus consisting of 5 minutes of global ischemia plus 10 minutes of reperfusion. Cold crystalloid cardioplegia was used to cause the hearts to arrest. This was followed by 45 minutes of global ischemia and 40 minutes of reperfusion. The change of myocardial hemodynamics, myocardial enzyme in the coronary effluent and myocardial energetic metabolism were determined. Results CF?HR?LVDP and ±dp/dt recovery were expressed as percent of their baseline values at poet reperfusion 5,10,20,30,40 minutes respectively. The recovery of the four indexes had a significant improvement in the IPC group CK MB leakage was decreased. The myocardial levels of ATP in preconditioned group at the end of the reperfusion were significantly preserved. Conclusions When IPC is used together with cardioplegia, it can still have a protective effect on the immature rabbit hearts suffered from global I/R injury. The findings may be beneficial for the combination of IPC and traditional myocardium protection measure in clinic such as hyperkalemic cardioplegia.
出处 《重庆医学》 CAS CSCD 2003年第2期179-181,共3页 Chongqing medicine
  • 相关文献

参考文献1

二级参考文献7

  • 1Drexler H,Dxepenbusch JW,Truog AG,et al.Effects of dilitiazem on cardiac function and regional blood at rest and during exercise in a conscious rat prearation of chronic heart failure(myocardial infarction)[].Circulation.1985
  • 2Macfden RJ.Role of the circulating and tissue-based renin-angiotensin system in the development of heart failure: implications for therapy[].Cardiology.1993
  • 3Hasenfuss G.Alterations of cacium-regulatory proteins in heart failure[].Cardiovascular Research.1998
  • 4Afzal N,Dhalla NS.Different changes in left and right ventricular SR calcium transport in congestive heart failure[].American Journal of Physiology.1992
  • 5Barry WH,Bridge JHB.Intracellular calcium homeostasi in cardiac myocytes[].Circulation.1993
  • 6Hisamatsu Y,Ohkusa T,Kihara Y,et al.Early changes in the functions of cardiac sarcoplasmic reticulum in volume-overloaded cardic hypertrophy in rats[].Journal of Molecular and Cellular Cardiology.1997
  • 7Spinale FG,Holzgrefe HH,Mukherjee R,et al.Angiotensinconverting enzyme inhibition and the progression of congestive cardiomyopathy effects on left ventricular and myocyte structure and function[].Circulation.1995

共引文献3

同被引文献20

  • 1秦川,肖颖彬,钟前进,陈林,王学锋.Protective effects of erythropoietin pretreatment on myocardium with hypoxia/reoxygenation injury in rats[J].Journal of Medical Colleges of PLA(China),2004,19(6):329-332. 被引量:6
  • 2秦川,肖颖彬,钟前进,陈林,王学锋.EPO预处理对心肌缺氧复氧损伤保护作用的研究[J].重庆医学,2005,34(5):734-737. 被引量:11
  • 3张祖列,闵苏.环氧化酶-2特异性抑制剂在心血管疾病中的应用及研究进展[J].重庆医学,2005,34(11):1742-1744. 被引量:6
  • 4Lawrence GT, George DJ. Transfusion medicine:support of patient undergoing cardiac surgery[J]. Am J Cardiovasc Drugs, 2001, 1(5): 337
  • 5Edward C. Perioperative use of erythropoietin[J]. Am J Therap, 2002, 9(5): 371
  • 6Abdelrahman M, Sharpies EJ, McDonald MC, et al.Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia [J].Shock,2004,22(1) :63
  • 7Chanil Moon, Melissa Krawczyk,Dongchoon Ahn, et al.Erythropoietin reduced myocardiol infarction and left ventricular functional decline after coronary artery ligation in rats[J]. Proc Natl Acad Sci USA,2003,100(20):11612
  • 8Lipsic E, van der Meer P, Henning RH,et al. Timming of erythropoietin treatment of cardioprotection in ischemia/reperfusion[J]. J Cardiovasc Pharmacol, 2004, 44(4) :473
  • 9Zhao ZC, Jing QK, Kenneth M. Erythropoietin is a novel vascular protectant through activation of aktl and mitochondrial modulation of cysteine proteases[J]. Circulation, 2002, 106(23): 2973
  • 10Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion Injury[J].Circulation, 2004,109(17): 2050

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部